Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis

Sarah Wood Pallas (), Marissa Courey, Chhaily Hy, Wm. Perry Killam, Dora Warren and Brittany Moore
Additional contact information
Sarah Wood Pallas: US Centers for Disease Control and Prevention (CDC)
Marissa Courey: US Centers for Disease Control and Prevention (CDC)
Chhaily Hy: US Centers for Disease Control and Prevention (CDC), National Institute of Public Health
Wm. Perry Killam: US Centers for Disease Control and Prevention (CDC), National Institute of Public Health
Dora Warren: US Centers for Disease Control and Prevention (CDC), National Institute of Public Health
Brittany Moore: US Centers for Disease Control and Prevention (CDC)

Applied Health Economics and Health Policy, 2018, vol. 16, issue 4, No 10, 537-548

Abstract: Abstract Background The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert’s cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB burden, and low multidrug-resistant (MDR) TB burden (1.4% of new TB cases, 11% of retreatment cases) introduced Xpert into its TB diagnostic algorithms for people living with HIV (PLHIV) and people with presumptive MDR TB in 2012. The study objective was to estimate these algorithms’ costs pre- and post-Xpert introduction in four provinces of Cambodia. Methods Using a retrospective, ingredients-based microcosting approach, primary cost data on personnel, equipment, maintenance, supplies, and specimen transport were collected at four sites through observation, records review, and key informant consultations. Results Across the sample facilities, the cost per Xpert test was US$33.88–US$37.11, clinical exam cost US$1.22–US$1.84, chest X-ray cost US$2.02–US$2.14, fluorescent microscopy (FM) smear cost US$1.56–US$1.93, Ziehl–Neelsen (ZN) smear cost US$1.26, liquid culture test cost US$11.63–US$22.83, follow-on work-up for positive culture results and Mycobacterium tuberculosis complex (MTB) identification cost US$11.50–US$14.72, and drug susceptibility testing (DST) cost US$44.26. Specimen transport added US$1.39–US$5.21 per sample. Assuming clinician adherence to the algorithms and perfect test accuracy, the normative cost per patient correctly diagnosed under the post-Xpert algorithms would be US$25–US$29 more per PLHIV and US$34–US$37 more per person with presumptive MDR TB (US$41 more per PLHIV when accounting for variable test sensitivity and specificity). Conclusions Xpert test unit costs could be reduced through lower cartridge prices, longer usable life of GeneXpert® (Cepheid, USA) instruments, and increased test volumes; however, epidemiological and test eligibility conditions in Cambodia limit the number of specimens received at laboratories, leading to sub-optimal utilization of current instruments. Improvements to patient referral and specimen transport could increase test volumes and reduce Xpert test unit costs in this setting.

Date: 2018
References: View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s40258-018-0397-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:16:y:2018:i:4:d:10.1007_s40258-018-0397-3

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-018-0397-3

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().